{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:00Z","timestamp":1761541140832},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.coph.2012.12.007","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T12:51:24Z","timestamp":1358427084000},"page":"280-286","source":"Crossref","is-referenced-by-count":16,"title":["Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications"],"prefix":"10.1016","volume":"13","author":[{"given":"Carolin","family":"Zwadlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2012.12.007_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.coph.2012.12.007_bib0010","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0020","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","article-title":"Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction","volume":"42","author":"Fraccarollo","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2012.12.007_sbref0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/eurheartj\/ehr176","article-title":"Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure","volume":"33","author":"Ivanes","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2012.12.007_bib0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2005.10.017","article-title":"Impact of plasma aldosterone levels for prediction of in-stent restenosis","volume":"97","author":"Amano","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0040","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cjca.2012.04.014","article-title":"Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque","volume":"28","author":"Rita","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0045","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima\u2013media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.coph.2012.12.007_bib0050","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","article-title":"Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation","volume":"26","author":"Suzuki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.coph.2012.12.007_bib0055","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.coph.2012.12.007_bib0060","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0065","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2012.12.007_sbref0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2012.12.007_bib0085","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2012.12.007_bib0090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure, Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.007_bib0095","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/eurjhf\/hfp136","article-title":"Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial","volume":"11","author":"Adamopoulos","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2012.12.007_bib0105","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0110","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1365-2362.2012.02676.x","article-title":"Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances","volume":"42","author":"Galuppo","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"Suppl B","key":"10.1016\/j.coph.2012.12.007_bib0115","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1093\/eurheartj\/sur005","article-title":"Aldosterone blockade: current research and future trends","volume":"13","author":"Bramlage","year":"2011","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.coph.2012.12.007_bib0120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ahj.2010.06.049","article-title":"Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial","volume":"160","author":"Beygui","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.coph.2012.12.007_bib0125","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2012.12.007_sbref0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2012.12.007_bib0135","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2012.12.007_sbref0140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2012.12.007_bib0145","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.coph.2012.12.007_bib0155","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","article-title":"Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase","volume":"20","author":"Johar","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2012.12.007_bib0160","doi-asserted-by":"crossref","first-page":"H2035","DOI":"10.1152\/ajpheart.00552.2010","article-title":"Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression","volume":"300","author":"Favre","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.coph.2012.12.007_bib0165","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0170","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2362.2004.01400.x","article-title":"Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation","volume":"34","author":"Bauersachs","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.coph.2012.12.007_bib0175","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling","volume":"52","author":"Di","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.coph.2012.12.007_bib0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.CIR.104.2.137","article-title":"Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes","volume":"104","author":"Harada","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2012.12.007_bib0190","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/eurheartj\/ehr292","article-title":"Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction","volume":"33","author":"Edelmann","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2012.12.007_bib0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.coph.2012.12.007_bib0200","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.coph.2012.12.007_bib0205","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","volume":"12","author":"Edelmann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.coph.2012.12.007_bib0210","unstructured":"Pieske BM: Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure (http:\/\/my.americanheart.org\/professional\/Sessions\/AdditionalMeetings\/AdditionalMeetingsResources\/Science-News-ESC-2012-Sunday_UCM_443739_Article.jsp)"},{"key":"10.1016\/j.coph.2012.12.007_bib0215","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T08:24:42Z","timestamp":1562574282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489213000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1471489213000039"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2012.12.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}